D&D Pharmatech Inc
347850
Company Profile
Business description
D&D Pharmatech Inc is building on a robust foundation of proprietary peptide research and strategic collaborations. The group is advancing a diverse pipeline of therapeutics for metabolic, fibrotic, and neurodegenerative diseases. The world-wide biotech company's umbrella structure comprises three U.S. subsidiaries, which include its clinical research arm responsible for conducting clinical trials for the company's pipeline, including its dual agonist (GLP-1/glucagon) for metabolic dysfunction-associated steatohepatitis (MASH).
Contact
27, Geumto-ro 80beon-gil
4th floor, Geumto-dong
Sujeong-gu, Gyeonggi-do
Seongnam-si13454
KORT: +82 3180197771
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
21
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Microsoft’s earnings report is expected to touch on AI adoption and monetization.
stocks
World’s largest miner overvalued after solid quarter
The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.
stocks
Hidden value in an expensive ASX
How investors can uncover value beyond the index heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,024.20 | 27.20 | -0.30% |
| CAC 40 | 8,193.56 | 37.13 | 0.46% |
| DAX 40 | 24,120.01 | 74.89 | -0.31% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,418.16 | 58.30 | -0.56% |
| HKSE | 25,915.20 | 248.04 | -0.95% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,140.23 | 445.63 | -0.75% |
| NZX 50 Index | 12,884.93 | 60.67 | -0.47% |
| S&P 500 | 7,137.90 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,793.40 | 26.10 | -0.30% |
| SSE Composite Index | 4,093.25 | 13.01 | -0.32% |